March 19, 2024
CMS released its annual monitoring report on the Medicare Part B Home Infusion Therapy (HIT) Services benefit showing that both provider participation and beneficiary utilization have declined over the past year.
Only 203 suppliers have participated in the benefit out of nearly 1,500 eligible infusion pharmacies and thousands of home health agencies. Most providers have made only a handful of visits with just 7 accounting for more than half (55%) of all HIT visits. This lack of participation leaves many states with no participating providers for Part B HIT services.
Without a per infusion day payment for pharmacy services, access will continue to wane. Medicare beneficiaries deserve the same site of care options as commercial insurance patients – which is why NHIA is advocating for the passage of the Preserving Patient Access to Home Infusion Act.
Help us support this critical legislation by sending a message to your Congressional representatives.
Last week concluded the 2026 National Home Infusion Association Annual Conference (NHIA 2026), which convened the largest gathering dedicated to the home and alternate site infusion industry in Denver, Colorado.
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, are pleased to announce the addition of Melinta to NHIA’s Future of Infusion Advisory Council (FIAC).
The National Home Infusion Foundation (NHIF) announces the winner and honorable mention for its Outstanding Abstract Achievement Award for 2026.
